Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

PTC Therapeutics, Inc.

NASDAQ: PTCT · Life Sciences · 10 alerts · CIK 1070081

Share price
$60.97Close, Nov 16
Market cap
$5.09B
Shares outstanding
83.54MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All PTC Therapeutics, Inc. filings on SEC EDGAR ↗

4:37 PM ET 8-K
M&A Deal

PTC Therapeutics M&A Deal with Sangamo Therapeutics, Inc.

PTC Therapeutics has completed its acquisition of ST-920 (isaralgagene civaparvovec), a BLA-stage AAV gene therapy for Fabry disease, from Sangamo Therapeutics. The company expects to complete a rolling Biologics License Application (BLA) submission to the FDA for accelerated approval in the fourth quarter of 2026. The acquisition adds a potential one-time treatment for Fabry disease to PTC's rare disorder pipeline.

Counterparty
Sangamo Therapeutics, Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.